Company Filing History:
Years Active: 1992
Title: The Contributions of Frank Corrigan to Pharmaceutical Innovation
Introduction: Frank Corrigan, an accomplished inventor based in Argyll, Great Britain, has made significant strides in the field of pharmaceuticals. With a focus on essential fatty acids and their therapeutic applications, his work contributes to the ongoing pursuit of innovations in health and wellness.
Latest Patents: Frank Corrigan holds a patent for "EFA compositions and therapy." This patent details a pharmaceutical composition that includes gamma-linolenic acid (GLA) or dihomo-gamma-linolenic acid (DGLA) and bioavailable selenium. Additionally, the composition may incorporate an 18:4 or higher n-3 essential fatty acid and/or bioavailable zinc. This formulation showcases the potential of combining specific nutrients for improved health outcomes.
Career Highlights: Frank is currently associated with Efamol Holdings Plc, a company recognized for its pioneering research in essential fatty acids and their benefits. His role in developing innovative therapies reflects his commitment to advancing pharmaceutical science and enhancing patient care.
Collaborations: Frank's work often involves collaboration with like-minded researchers, including his notable coworker, David F. Horrobin. Such collaborations foster an environment of innovation and support the development of groundbreaking health solutions.
Conclusion: Frank Corrigan's contributions to the pharmaceutical industry, particularly through his patent for EFA compositions and therapy, highlight the importance of innovation in addressing health challenges. With the ongoing support from companies like Efamol Holdings Plc, his work will continue to shape the future of nutritional therapies.